First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate

British Journal of Haematology

Volumn 167, Issue 1, 2014, Pages 139-141

  Eskazan, Ahmet Emre ^a   Ayer, Mesut ^b   Kantarcioglu, Bulent ^c   Arica, Deniz ^c   Demirel, Naciye ^c   Aydin, Demet ^c   Yalniz, Fevzi Firat ^a   Elverdi, Tugrul ^a   Salihoglu, Ayse ^a   Ar, Muhlis Cem ^a   Ongoren Aydin, Seniz ^a   Baslar, Zafer ^a   Aydin, Yildiz ^a   Tuzuner, Nukhet ^a   Ozbek, Ugur ^a   Soysal, Teoman ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b HASEKI EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^c OKMEYDANI TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Chronic myeloid leukaemia; Efficacy; Generic; Imatinib mesylate

Indexed keywords

GENERIC DRUG; IMATINIB; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ARTICLE; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG RESPONSE; DRUG TOLERABILITY; EDEMA; GASTROINTESTINAL SYMPTOM; HUMAN; MOLECULAR GENETICS; MUSCLE CRAMP; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; LEUKEMIA, MYELOID, CHRONIC-PHASE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BENZAMIDES; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TREATMENT OUTCOME;

EID: 84908876492     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12937     Document Type: Article

References (6)

1. Asfour, I.A. & Elshazly, S.A. (2009) Changing therapy from Glivecto a "copy" imatinib results in a worsening of chronic myeloid leukemia disease status: two case reports. Cases Journal, 2, 9342.
2. Baccarani, M., Deininger, M.W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J.F., Cervantes, F., Clark, R.E., Cortes, J.E., Guilhot, F., Hjorth-Hansen, H., Hughes, T.P., Kantarjian, H.M., Kim, D.-W., Larson, R.A., Lipton, J.H., Mahon, F.-X., Martinelli, G., Mayer, J., Müller, M.C., Niederwieser, D., Pane, F., Radich, J.P., Rousselot, P., Saglio, G., Saußele, S., Schiffer, C., Silver, R., Simonsson, B., Steegmann, J.-L., Goldman, J.M. & Hehlmann, R. (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood, 122, 872-884.
3. Eskazan, A.E., Elverdi, T., Yalniz, F.F., Salihoglu, A., Ar, M.C., Ongoren Aydin, S., Baslar, Z., Aydin, Y., Tuzuner, N., Ozbek, U. & Soysal, T. (2014) The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia. Leukaemia & Lymphoma, doi:10.3109/10428194.2014.905774.
4. Experts in Chronic Myeloid Leukemia (2013) The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood, 121, 4439-4442.
5. Gogtay, J., Chahchad, S., Jadhav, S. & Purandare, S. (2010) Response to the case report by Mattar: generic Imatinib (Imatib, Cipla) in a patient with chronic myeloid leukemia in chronic phase. International Journal of Hematology, 92, 772-773.
6. Mattar, M. (2010) Failure of copy Imatib (CIPLA, India) to maintain hematologic and cytogenetic responses in chronic myeloid leukemia in chronic phase. International Journal of Hematology, 91, 104-106.